Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL398390 | 0.81 | TSHR (0.40) | TSHRTDP1 | |
| Fluoride SCHEMBL1973104 | 0.78 | TSHR (0.38) | TSHRTDP1 | |
| SCHEMBL14350954 | 0.73 | TSHR (0.33) | TSHRTDP1 | |
| SCHEMBL28709716 | 0.71 | CYP2D6 (0.35) | TSHRTDP1 | |
| SCHEMBL20347936 | 0.71 | TSHR (0.39) | TSHRTDP1 | |
| SCHEMBL13366742 | 0.71 | ALDH1A1 (0.35) | TSHRTDP1 | |
| SCHEMBL25756291 | 0.71 | TSHR (0.32) | TSHRTDP1 | |
| SCHEMBL20347937 | 0.71 | TSHR (0.39) | TSHRTDP1 | |
| SCHEMBL1033095 | 0.69 | TSHR (0.39) | TSHRTDP1 | |
| SCHEMBL270380 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1687292-B1 | VITAMIN D RECEPTOR MODULATORS | LILLY CO ELI (US) | 2007-08-22 | — | — | EP | claimed |
| US-7772425-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2010-08-10 | — | — | US | disclosed |
| EP-2184281-A1 | Phenyl-thiophene type vitamin D receptor modulators | Eli Lilly & Company (US) | 2010-05-12 | — | — | EP | disclosed |
| US-7601850-B2 | less hypercalcemic than 1a,25 dihydroxy vitamin D3; bone disorders, psoriasis | ELI LILLY AND COMPANY (US) | 2009-10-13 | — | — | US | disclosed |
| US-20090227604-A1 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY | 2009-09-10 | — | — | US | disclosed |
| US-7566803-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2009-07-28 | — | — | US | disclosed |
| US-20090018058-A1 | Vitamin D Receptor Modulators | ELI LILLY AND COMPANY (US) | 2009-01-15 | — | — | US | disclosed |
| US-20060287536-A1 | Phenyl-thiophene type vitamin d receptor modulators | ELI LILLY AND COMPANY | 2006-12-21 | — | — | US | disclosed |
| US-20060135484-A1 | Vesicant treatment with phenyl-thiophene type vitamin d receptor modulators | ELI LILLY AND COMPANY PATENT DIVISON (US) | 2006-06-22 | — | — | US | disclosed |
| US-20060094778-A1 | Vesicant treatment with phenyl-phenyl type vitamin d receptor modulators | ELI LILLY AND COMPANY, AN INDIANA CORPORATION | 2006-05-04 | — | — | US | disclosed |
| EP-1587905-A3 | VESICANT TREATMENT WITH PHENYL-THIOPHENE TYPE VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-12-14 | — | — | EP | disclosed |
| EP-1587906-A2 | VESICANT TREATMENT WITH PHENYL-PHENYL TYPE VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-26 | — | — | EP | disclosed |
| EP-1587905-A2 | VESICANT TREATMENT WITH PHENYL-THIOPHENE TYPE VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-26 | — | — | EP | disclosed |
| EP-1565422-A1 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-08-24 | — | — | EP | disclosed |
| EP-1511740-A1 | PHENYL-THIOPHENE TYPE VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-03-09 | — | — | EP | disclosed |
| WO-2004063348-A2 | VESICANT TREATMENT WITH PHENYL-THIOPHENE TYPE VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| WO-2004063345-A2 | VESICANT TREATMENT WITH PHENYL-PHENYL TYPE VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| WO-2004048309-A1 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-06-10 | — | — | WO | disclosed |
| WO-2003101978-A1 | PHENYL-THIOPHENE TYPE VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227604-A1 | VITAMIN D RECEPTOR MODULATORS | VDR, CYP24A1, CYP2R1 | TSHR 512/4885TDP1 4674/4885 |
| US-20090018058-A1 | Vitamin D Receptor Modulators | VDR, CYP2R1, CYP24A1 | TSHR 453/4885TDP1 4601/4885 |
| US-20060135484-A1 | Vesicant treatment with phenyl-thiophene type vitamin d receptor modulators | VDR, CYP2R1, CYP24A1 | TSHR 458/4885TDP1 2923/4885 |
| US-20060094778-A1 | Vesicant treatment with phenyl-phenyl type vitamin d receptor modulators | VDR, CYP2R1, CYP24A1 | TSHR 1436/4885TDP1 3086/4885 |
| US-20060287536-A1 | Phenyl-thiophene type vitamin d receptor modulators | VDR, CYP2R1, CYP24A1 | TSHR 92/4885TDP1 3494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.